Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
Authors: Arbyn M,  de Sanjosé S,  Saraiya M,  Sideri M,  Palefsky J,  Lacey C,  Gillison M,  Bruni L,  Ronco G,  Wentzensen N,  Brotherton J,  Qiao YL,  Denny L,  Bornstein J,  Abramowitz L,  Giuliano A,  Tommasino M,  Monsonego J
Journal: Int J Cancer
Date: 2012 Nov 1
Branches: MEB
PubMed ID: 22623137
PMC ID: PMC3429628
Abstract: The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes ~600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomized trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programs. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, anogenital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organized approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.